- Home
- SRPT vs AGIO Comparison
SRPT vs AGIO Comparison
Compare SRPT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRPT
- AGIO
- Stock Information
- Founded
- SRPT 1980
- AGIO 2007
- Country
- SRPT United States
- AGIO United States
- Employees
- SRPT N/A
- AGIO N/A
- Industry
- SRPT Biotechnology: Pharmaceutical Preparations
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- SRPT Health Care
- AGIO Health Care
- Exchange
- SRPT Nasdaq
- AGIO Nasdaq
- Market Cap
- SRPT 2.0B
- AGIO 2.3B
- IPO Year
- SRPT 1997
- AGIO 2013
- Fundamental
- Price
- SRPT $18.46
- AGIO $36.13
- Analyst Decision
- SRPT Hold
- AGIO Buy
- Analyst Count
- SRPT 30
- AGIO 6
- Target Price
- SRPT $44.37
- AGIO $57.00
- AVG Volume (30 Days)
- SRPT 9.6M
- AGIO 652.4K
- Earning Date
- SRPT 08-06-2025
- AGIO 10-30-2025
- Dividend Yield
- SRPT N/A
- AGIO N/A
- EPS Growth
- SRPT N/A
- AGIO N/A
- EPS
- SRPT N/A
- AGIO 11.13
- Revenue
- SRPT $2,481,531,000.00
- AGIO $40,875,000.00
- Revenue This Year
- SRPT $9.41
- AGIO $28.19
- Revenue Next Year
- SRPT N/A
- AGIO $152.14
- P/E Ratio
- SRPT N/A
- AGIO $3.25
- Revenue Growth
- SRPT 64.89
- AGIO 30.57
- 52 Week Low
- SRPT $10.42
- AGIO $23.42
- 52 Week High
- SRPT $138.81
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- SRPT 48.03
- AGIO 45.10
- Support Level
- SRPT $17.95
- AGIO $37.38
- Resistance Level
- SRPT $19.61
- AGIO $41.10
- Average True Range (ATR)
- SRPT 1.20
- AGIO 1.70
- MACD
- SRPT -0.06
- AGIO 0.04
- Stochastic Oscillator
- SRPT 19.69
- AGIO 39.98
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.